Urothelial carcinoma Trials in Baltimore, United States
Conditions / Urothelial carcinoma / Baltimore, United States
Urothelial carcinoma is a medical condition with active clinical research programs worldwide.
27 total trials for this combination
Showing top 10 of 27 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | COMPLETED | PHASE1 |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | RECRUITING | — |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | TERMINATED | PHASE2 |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | COMPLETED | PHASE1 |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | COMPLETED | PHASE1 |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | COMPLETED | PHASE3 |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | COMPLETED | PHASE1 |